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Overexpression of ecto-5'-nucleotidase promotes P-glycoprotein ex-
pression in renal epithelial cells. P-glycoprotein (P-gp), responsible for
multidrug resistance (MDR) of tumoral cells, is also expressed in apical
membranes of normal epithelial cells, among which are proximal tubular
cells. Ecto-5'-nucleotidase (5'Nu), co-located with P-gp in renal brush
border membranes, could be instrumental in the expression of MDR
phenotype. P-gp activity [assessed by rhodamine 123 (R123) and [3H]vin-
blastine (3H-VBL) accumulation] was evaluated in MDCK cell lines in
which human 5'Nu was expressed at different levels after retroviral
infection: MDCK-5'NU/—- cells with a low 5'Nu activity < 2
pmol/mg protein/mm) and MDCK-5'NU/+ cells, which expressed a high
level of 5'Nu (Vr,,ax 150 18.5 pmol/mg protein/mm). MDCK-5'NU/—
cells did not display functional expression of MDR. In MDCK-5'NU/+
cells, R123 and 3H-VBL accumulation was significantly lower than in
MDCK-5'NU/— cells and was dramatically enhanced by P-gp inhibitors.
This high P-gp activity in MDCK-5'NU/+ cells was confirmed by their
resistance to coichicine (measured by LDH release and MTT assay) as
compared to MDCK-5'NU/— and was accounted for by increased mem-
brane expression of P-gp assessed by Western blot. Neither AMP nor
adenosine, the substrate and the product of 5'Nu, respectively, affected
P-gp activity. Inhibition of 5'Nu with of3-methylene-adenosine-diphos-
phate (aMADP) or with a blocking anti-5'Nu antibody (1E9) did not
blunt MDR expression in MDCK-5'NU/+ cells. Conversely, the anti-5'Nu
antibody 5F/F9, which did not block the enzymatic site, induced a decrease
of P-gp activity. Further, incubation of MDCK-5'NU!— cells with condi-
tioned medium from MDCK-5'NU/+ cells, which contained significant
amounts of released 5'Nu, induced MDR phenotype. In conclusion: (i)
expression of ecto-5'Nu promotes multidrug resistance (MDR) activity in
renal epithelial cells by enhancement of P-gp expression; (ii) this effect
does not involve enzymatic activity of 5'Nu; (iii) supernatants of cells that
express 5'Nu confered P-gp activity to 5'Nu negative cells.
P-glycoprotein (P-gp) is an adenosine 5'-triphosphate (ATP)-
dependent plasma membrane efflux pump, a member of the ATP
binding cassette (ABC) transporter superfamily. Overexpression
of P-gp in turnoral cells confers a multidrug-resistance (MDR)
phenotype. P-gp pumps cytotoxic drugs such as ymca alkaloids,
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doxorubicin and epidophyllotoxin [1, 2] out of the tumoral cells
and thus prevents drug intracellular accumulation and toxicity.
P-gp has been detected in a variety of normal cells including
epithelial cells from small intestine, colon, biliary canalicules and
kidney proximal tubules [11. In epithelial cells, especially in renal
proximal tubular cells, P-gp has been detected in apical mem-
branes [1]. This localization suggests a role of P-gp in the
extrusion of molecules to the tubular lumen, but the precise
function and the endogenous substrate(s) of P-gp in normal cells
remains unknown. It has been suggested that P-gp could be either
a chloride channel or a channel regulator involved in cell volume
regulation [1, 2], or a nucleotide channel [3]; however, the little
information available concerning P-gp regulation is controversial
[2, 4—61.
In the kidney, ecto-5'-nucleotidase (5'Nu) is also expressed
mainly in the apical brush border membranes of proximal tubular
cells [7]. The primary function of this plasma membrane-bound
ecto-enzyme is to catalyze the dephosphorylation of AMP into
adenosine in the extracellular medium [7, 8]. Other functions of
ecto-5'Nu have been described in nonrenal cells, such as enhance-
ment of neurite differentiation [91 or proliferation [8, 10], and
these effects seem partially independent from its enzymatic activ-
ity.
Some reports have pointed out a correlation between 5'Nu
expression and outcome of neoplasia, especially lymphoma [11].
Furthermore, Ujhazy et al have suggested that there is a link
between 5'Nu and P-gp expression [12, 13]. These authors have
found that tumoral cell lines overexpressing P-gp frequently
exhibited high 5'Nu expression. As a working hypothesis, they
proposed that, in MDR cell lines, 5'Nu serves as an accessory
molecule, by providing ATP precursors for ATP-dependent trans-
porters. However, the possibility that the expression of one of
these proteins promotes the expression of the other was not
evaluated, On the other hand, the co-localization of the two
proteins in the brush border of normal epithelial cells, and their
common potential implication in nucleotidc metabolism, suggest
that a functional interaction between 5'Nu and P-gp could also
exist in normal cells.
Because 5'Nu activity was shown to modulate renal sodium!
phosphate cotransport that is expressed in brush border mem-
branes [14], we asked the question of whether 5'Nu could also
modulate the activity of P-gp, another apical transporter, in renal
tubule cells. To answer this question, we transfected in a stable
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manner MDCK cells, which were deprived of the endogenous
enzyme, with human 5'Nu. The results show that overexpression
of 5'Nu induced P-gp expression, and that catabolism of AMP
into adenosinc is not responsible for the emergence of MDR
phenotype.
METHODS
Reagents
Polybrene (hexadimethrine bromide), Rhodamine 123 (R123),
csJ3 methylene adenosine diphosphate (a/3MADP), coichicine,
MIT, levamisole, dipyridamole (dp) and other P-gp inhibitors
were obtained from Sigma (Saint-Quentin Fallavier, France).
Geneticin G-418 sulphate (G418), Hank's balanced saline solu-
tion and all culture products were purchased from Gibco BRL
(Cergy Pontoise, France). [3H]vinblastine (3H-VBL) and [14Cj5'-
AMP were provided by Amersham (Les Ulis, France).
Cell lines
5'Nu-expressing MDCK were obtained using a recombinant
amphotrophic retroviral vector harboring the human 5'Nu cDNA
under the control of the Moloney long terminal repeat (LTR).
The vector was derived from the LXSN backbone [15] in which
the neomycin cDNA is placed under the SV40 promoter, down-
stream from the 5'Nu cassette. Retroviral particles were gener-
ated from the 4rCRIP packaging cell line [16], and individual
clones were isolated and tested for their ability to transfer 5'Nu
activity onto MDCK.
Retroviral infections were realized as described [15]. Briefly,
transduced MDCK were obtained after a two hours incubation
with the retroviral supernatant including polybrene (8 jtg/ml).
Amplification of genetically modified MDCK clones required the
presence in the culture media of 500 tg/ml of G418 (based on
control untransduced MDCK). Subsequently, three 5'Nu-express-
ing MDCK clones were obtained expressing different levels of
exogenous enzyme activity: MDCK-5'NU/— (low), MDCK-
5'NU/i (intermediate), and MDCK-5'NU/+ (high).
Each transduced MDCK clone was tested for its ability to
generate replication-competent retroviruses [17], and was re-
vealed to be negative.
Two other MDCK transfected cell lines were used in this study:
one obtained by transfection with human MDR1 (kind gift from
Dr. M.M. Gottesman [18]) and the other transfected with the
Na/So4 cotransport, Na/Sil (kind gift from Dr. J. Biber [19]).
All cell lines were grown in humidified atmosphere at 37°C
containing 5% C02, in a medium made of a 1:1 (vol/vol) mixture
of 1-lam's F12 and Dulbecco's modified Eagle's medium contain-
ing 15 mvi Hepes, 21.5 m'vi HCO3, 1 mrvi Na pyruvate, 1% of MEM
amino acid mixture, 4 m'vi L-glutamine, 50 U/mI penicillin, 50
ig/ml streptomycin, 50 JiM Na selenite and 5% newborn calf
serum. Medium was changed three times a week and cells were
suhcultured weekly. The splitting ratio was I to 2, 4 or 6 for
MDCK-5'NU/-, MDCK-5'NU/i and MDCK-5'NU/+ cells, re-
spectively. All experiments were performed on confluent cells
after four days of culture.
Rhodamine 123 accumulation
Confluent cells grown in 24 well trays were loaded for 18 hours
in the culture medium with 10 jLM rhodamine (R123) with or
without dipyridamole (dp) or other MDR inhibitors. Cells were
then washed twice with ice-cold buffer (buffer T) containing 137
mM NaC1, 5.4 mrvi KC1, 1.2 mM MgSO4, 14 ms'i Tris-HC1, pH 7.4,
1 mM CaCl2 and 40 jIM dp. Cells were then lysed with 500 jrl per
well of 0.5% Triton X100 and incubated during two hours in the
dark at 4°C. Aliquots of 50 jtl of lysate were transferred to a
cuvette with 2 ml of distilled water. R123 was excited at 495 nm
and fluoresence emission was measured at 535 nm in a F2000
Hitachi spectrofluorometer (Hitachi Corp). Proteins were deter-
mined in each well by the Bradford technique modified for
microtitration [20].
3H-vinblastine accumulation
After removal of the culture medium, confluent cells in 24 well
plates were washed with Hank's balanced saline solution (HBSS)
containing 15 mM Hepes and 0.1% glucose, pH 7.4. Cells were
then incubated in a humidified atmosphere at 37°C for one hour
with the solution of HBSS containing 0.1% BSA, 37 nM 3H-
vinbiastine (3H-VBL) with or without 20 jIM dp. Then cells were
washed three times with ice-cold buffer T and lysed with 300 jIl of
0.5% Triton X100. Lysates (250 jIl) were added to the scintillation
liquid (2 ml) and radioactivity was quantified in a scintillation
counter (EGG instruments; Wallac Berthold Bioanalytical, Evry,
France).
Cytotoxicity assays
Cells were seeded in 24 well plates. After the first 24 hours, cells
were exposed to 0, 25, 50, or 100 ng/ml of coichicine with or
without dp. At 96 hours, cytotoxicity was determined either by
lactate dehydrogenase (LDH) release in the medium or by
viability assay based on mitochondrial integrity using MiT [21].
LDH activity was determined in the cells and in the supernatant
with the LDH Enzyiine kit (BioMérieux, Marcy l'étoile, France).
The ratio LDH in supernatant/LDH in supernatant + cells was
calculated for each well. For the MIT assay, cells were incubated
in humidified atmosphere at 37°C and 5% CO2 for one hour with
0.5 mg/mi of MTT and then the medium was removed. The
intracellular MTT-formazan complex was solubilized in 400 d of
dimethyl sulfoxide and absorbance was measured at 570 nm.
Determination of 5'Nu activity
The activity of ecto-5'Nu was determined on intact cells using a
method adapted from Gentry and Olson [22] as previously
described [23]. Briefly, after removal of culture medium, cells
were washed once with HBSS containing 1 m levamisole, and
then incubated at 37°C in the same solution (500 j.d/well) with
[14C]5'-AMP (0.02 jICi/mi), unlabeled 5'-AMP (at adequate
concentrations) and 20 jIM dp which abolishes cellular uptake of
generated adenosine [141. For determination of nonspecific activ-
ity, i0— M a methylene adenosine diphosphate (a/3MADP) was
added in one well for each condition. At this concentration,
aMADP totally inhibits 5'Nu activity [7] since the activity is not
different from medium alone. After five minutes of incubation,
450 1d of supernatant were mixed with 100 jtl of 0.15 M ZnSO4
and 100 jil of 0.15 M Ba(OH)2. The mixture was vigorously shaken
and centrifuged (15000 )< g; 2 mm) in order to separate adenosine
from 5'-AMP. Supernatants containing adenosine were counted
in a liquid scintillation counter and cells were lysed by 0.5% Triton
X100 (500 jil/well) to determine protein content.
The activity of 5'Nu in the supernatant was determined by the
same method except that reagents were added directly in the
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supernatant and 5'Nu activity was mesured after 20 minutes of
incubation.
Western blot
For the preparation of membrane fractions, cells cultured in
petri dishes were washed twice with cold PBS (10 msi Na2HPO4,
1.4 mrvi KH2PO4, 137 mivi NaCl, 2.7 mrvi KCI), pelleted, and there
homogeneized by sonication in 300 jxl PBS containing 2 mM
ethylenediaminetetraacetic acid (EDTA) and 1 mrvi phenylmeth-
ylsulforyl fluoride (PMSF). Plasma membrane fractions were
obtained by ultracentrifugation of homogenates (100,000 g for 30
mm at 4°C). The pellets were dissolved by sonication in lysis buffer
(100 mivi Tris pH 7.4, 300 msi NaCl, 2 mst EDTA, 1% Triton
X-100, 0.1% SDS, 5 mi iodoacetamide, 1 jLM leupeptin, 1 mM
PMSF). Protein contents were determined by the method of
Bradford [20] and sodium dodecyl sulfate—polyacrilamide gel
electrophoresis (SDS-PAGE) was performed as described [241.
Then, the proteins were transferred onto a nitrocellulose mem-
brane. The nonspecific sites were blocked by incubation at room
temperature for one hour in PBS—Tween 0.1% (PBST) with
7.5% nonfat dairy milk powder. The membrane was then incu-
bated overnight at 4°C with the specific monoclonal anti-P-gp
antibody C219 (0.75 jig/mI; Valbiotech, Paris, France) in the same
milk solution. Specific antigen-antibody complexes were detected
by enhanced chemoluminescence (ECL kit, Amersham, Les Ulys,
France) after incubation for two hours in PBST-7.5% milk
containing horseradish peroxidase secondary antibody.
Data presentation
R123 accumulation was expressed as fluorescence arbitrary
units per mg of protein (FAU/mg protein), 3H-VBL accumulation
as pmol/mg protein. 5'Nu activity was expressed as nanomoles of
adenosine per mg protein per minute for cells and nanomoles of
adenosine per well per minute for supernatants. Cytotoxic assays
were expressed as percent of control.
Results were presented as mean SEM of 3 to 20 different
experiments (N) in which triplicates were obtained.
Statistical analyses were performed by unpaired t-test or by one
way or two way analysis of variance (ANOVA) when appropriate.
RESULTS
5'Nu activity
Three MDCK cell lines with different 5'Nu activities were
obtained: MDCK-5'NU/— with a very low activity, MDCK-5'NU/i
with a moderate activity and MDCK-5'NU/+ with a high activity
(Table 1). The very low 5'Nu activity in MDCK-5'NU/-- did not
allow us to calculate the apparent Km value. Affinities were not
different in the two other cell lines (Table 1).
R123 and 3H-VBL accumulations
R123 is a good substrate for MDR-associated P-gp [25—281.
Cellular retention of this dye was therefore used in numerous
studies to evaluate the activity of P-gp. Agents such as dp that
block P-gp have been found to increase the retention of Ri 23 only
in cells expressing P-gp [29, 30]. The intensity of R123 accumu-
lation was in the following order: MDCK-5'NU/-- > MDCK-
5'NU/i> MDCK-5'NU/+ (Table 1).
As shown in Figure 1, dp enhanced R123 accumulation in a
concentration-dependent manner in MDCK-5'NU/+. In contrast,
MDCK-5'NTJ/- MDCK-5'NU/i MDCK-5NU/+
5'Nu activity
pmollmgprot/min <2 54.0 11.5 150.0 18.5°
KmpM — 396±45 459±30
R123 accumulation
FAU/mg protein
control 10.55 1.54 4.55 0.25c 0.31 ()03h
11.99 1.83 7.00 034d 2.11 026w
The results are expressed as mean SCM of 3 different experiments for
5'Nu parameters and 20 different experiments for R123 accumulation
ap < 0.01 vs. MDCK-5'NU/i
hp < 0.001 vs. MDCK-5'NU/i
°P < 0.001 vs. MDCK-5'NU/--
dp < 0.001 vs. control
dp had no effect on R123 accumulation, at any concentration
tested, in MDCK-5'NU/—.
For the subsequent experiments, we chose the concentration of
20 jiM dp that induced a sevenfold increase in R123 accumulation
in MDCK-5'NU/+.
The accumulation of 3H-VBL, another substrate of P-gp [18,
31, 32], was measured in MDCK-5'NU/— and MDCK-5'NU/+.
As for R123 accumulation, MDCK-5'NU/— retained more 3H-
VBL than MDCK-5'NU/+ and dp increased significantly 3H-
VBL retention only in the MDCK-5'NU/+ cell line (Fig. 2).
As a control, we verified that transfection of MDCK cells with
another apical membrane protein did not affect P-gp activity. We
used a MDCK cell line transfeeted with the Na/SO4 cotransporter
(NaSi-1; gift from Dr. J. Biber [19]). These cells did not express
5'Nu activity and their P-gp activity was not enhanced as com-
pared to their appropriate controls (R123 accumulation: 0.54
0.05 vs. 0.37 0.04 FAU/mg protein; 3H-VBL accumulation:
2.45 0.47 vs. 1.19 0,04 pmol/mg protein, N = 3).
Effect of P-gp inhibitors on R123 accumulation
In order to verify that the pharmacological properties of P-gp in
MDCK cells resembled those described in other cell lines, we
tested the effect of other MDR inhibitors on R123 accumulation
in MDCK-5'NU/+ cells: 20 J.LM amiodarone [33], 2.5 jiM BIBW 22
[30], i0 M verapamil [1, 21, 20 jiM reserpin [34], 10 M
cyclosporine A [2] increased significantly R123 accumulation. In
contrast, 200 jIM genistein [35], a specific inhibitor of multidrug
related protein (MRP), had no effect on R123 retention (Table 2).
Cytotoxicity of coichicine
The cytotoxicity of colchicine depends on cellular accumulation
of the drug and is inversely proportional to the expression of P-gp
that actively extrudes this drug [2, 36]. Determination of cytotox-
icity either by LDH release or by MTT, after incubation of
MDCK-5'NU/— or MDCK-5'NU/+ with increasing concentra-
tions of colchicine, was used as another test to probe the activity
of P-gp.
As shown in Figure 3, the results were similar with the two
cytotoxic assays. MDCK-5'NU/+ were more resistant to eolchi-
cine than MDCK-5'NU/—, since the toxicity was concentration-
dependent in MDCK-5'NU/+ (P < 0.001 in 1 way analysis of
variance) while it was already maximal with the smallest tested
concentration of coichicine in MDCK-5'NU/—. Dipyridamole
Table 1. 5Nu activity and R123 accumulation (with or without dp) in
MDCK cell lines
dp
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Fig. 2. 3H.YBL accumulation in MDCK-5'NU/— and MDCK.5'NU/+
cells. Cells were incubated during one hour without (E) or with (•) 20 jLM
dp. Results are expressed as means SEM of 3 experiments. 555P < 0.001
vs. MDCK-5'NU/--, ***p < 0.001 vs. MDCK-5'NU/+ without dp.
(Dp) had no toxic effect alone and did not modify cytotoxicity of
coichicine in MDCK-5'NU/--. In contrast, dp reversed the drug
resistance in MDCK-5'NU/+ (P < 0.01 in 2-way analysis of
variance). The 5'Nu inhibitor, aI3MADP, did not enhance cyto-
toxicity of coichicine.
Relationship between 5'Nu enzymatic function and P-gp
activity
To evaluate whether enzymatic activity of 5'Nu affected P-gp
activity, we studied the effect of AMP, the main substrate of 5'Nu
[7, 8], adenosine, the product of 5'Nu, adenosine deaminase
which converts adenosine into inosine [37], and c43MADP which
inhibits 5'Nu activity [7].
R123 accumulation in MDCK-5'NU/+ was not modified after
96 hours of incubation with AMP or adenosine at any concentra-
tion tested between iO and 10 M (0.47 0.2 and 0.45 0,03
FAU/mg protein in the presence of iO M AMP or iO M
adenosine, respectively, vs. 0,31 0.05 FAU/mg protein under
basal conditions) or with iO M af3MADP or 1 mU/ml adenosine
deaminase (Fig. 4). Along the same line, aMADP, adenosine
Table 2. Effect of various P-gp inhibitors and MRP inhibitor on R123
accumulation in MDCK-5'NU/+
R123
accumulation
Inhibitors FA U/mg protein P
Control 0.66 0.14
Dipyridamole 20 jxM 4.35 0.75 <0.001
Amiodarone 20 I.LM 3.08 1.15 <0.05
BIBW 22 20 p.M 5.86 1.68 <0.0
Verapamil i0' M 6.03 1.01 <0.001
Reserpin 20 p.M 6.39 1.63 <0.001
Cyclosporine A io- M 9.35 1.14 <0.001
Genistein 200 p.M 1.18 0.18 NS
Values arc means SEM of 3 to 6 different experiments.
deaminase and AMP did not affect 3H-VBL accumulation (Fig.
4).
Effect of anti-5'Nu antibodies on P-gp activity
Two monoclonal antibodies were tested on 5'Nu and P-gp
activities: 1E9 (kind gift from Dr. L. Thompson) raised against
human 5'Nu [10, 38] and 5F!F9 (kind gift from Dr. B. Kaissling)
raised against rat 5'Nu [39, 40]. 1E9 antibody (15 p.g/ml added 96
hr and again 48 hr before the experiments in order to compensate
antibody degradation) induced an 87.5% inhibition of 5'Nu
activity in MDCK-5'NU/+ but did not affect P-gp activity mea-
sured by R123 or 3H-VBL accumulation (Table 3). In contrast,
5F/F9 antibody (1/200) had no effect on 5'Nu activity but signif-
icantly inhibited P-gp activity (Table 3). As a control, we tested
the effect of 5F/F9 antibody on P-gp activity in MDCK cells that
did not express 5'Nu. In these cells, 5F/F9 antibody, at the dilution
of 1/200, had no effect on P-gp activity (R123 accumulation:
0.75 0.04 vs. 0.85 0.06 FAU/mg protein, NS; 3H-VBL
accumulation: 0.98 0.39 vs. 1.04 0.21 pmol/mg protein, NS,
N = 3).
Effect of MDCK-5'NU/+ conditioned medium on
MDCK-5'NU/-— cells
Supernatants of MDCK-5'NU/— and MDCK-5'NU!+ grown
for three days in usual medium (with or without aMADP iO
M for MDCK-5'NU/+) were collected, centrifuged (3000 rpm; 10
mm) and filtered (0.22 /xm). MDCK-5'NU/— were then cultured
during four days with these conditioned media or with usual
BA
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Fig. 1. Effect of dp concentration on R123
accumulation. (A) MDCK-5 'N UI— and
(B) MDCK-5'NU/+ cells were incubated for 18
___________________
hours with 10 p.M R123 and various
concentrations of dp. Results are expressed as
0 10 20 50 means SCM of 3 experiments and tested by
one way analysis of variance (P < 0.001 for
dp, LM MDCK-5'NU/+, NS for MDCK-5'NU/--).
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Fig. 3. Cytotoxicity of coichicine in MDCK-
5'NU/— and MDCK-5'NU/+ cells. Cytotoxicity
was measured after 72 hours of incubation by
LDH release A, B) and MTT assay (c, D) in
MDCK-5'NU/- (A, C) and MDCK-5'NU/+
(B, D) cells without (I) or with 20 !.LM dp (0)
or i0 M a/3MADP (A). Results are shown as
means SCM of 3 experiments and tested by
100 analysis of variance (P < 0.00 1 for ct MDCK-5'NU/+ vs. Ct MDCK-5'NU/—, P < 0.01 for dp
vs. ct in MDCK-5'NU/+, for both cytotoxic
assays).
Fig. 4. Effect of AMP, adenosine deaminase
and aI3MADP on P-gp activity in MDCK-S'NU/
+ cells. Cells were incubated during 96 hours
without (LII) or with i0- M csJ3MADP (), 1
U/mI adenosine deaminase (U) or i0 M AMP
(11:1) prior to determination of R123
accumulation (A) and 3H-VBL accumulation
(B). Results are shown as means SEM of 3
experiments.
medium as a control. Membrane-bound 5'Nu activity in MDCK-
5'NU/— was identical whatever the medium: 0.24 0.14, 0.26
0,26 and 0.11 0.16 nmol/mg protein/mill for cells incubated with
conditioned medium from MDCK-5 'NU/+, MDCK-5 'NU/— and
with control medium, respectively. This result rules out a possible
tranfer of MDCK-5NU/+ cells into the wells containing MDCK-
5'NU/— cells. 5'Nu activity, measured in medium from MDCK-
5'NU/+ cells, was significantly higher than in that from MDCK-
5'NU/— cells and was not altered by four days of incubation with
MDCK cells (Table 4).
As shown in Figure 5, MDCK-5'NU/-— cells grown in MDCK-
5'NU/+ conditioned medium displayed a significant decrease of
R123 accumulation when compared with those grown in MI)CK-
5'NU/— conditioned medium. l)p, but riot rsMADP, reversed
the effect of MDCK-5'NU/+ conditioned medium.
Incubation of MDCK-5'NU/— during four days with 4 mU/mI
of 5'Nu from Crotalus Atrox venom did not influence R123
accumulation (15.78 5.11 vs. 14.84 2.09 FAU/mg protein in
Table 3. Effect of two different anti-5'Nu monoclonal antibodies on
5'Nu and P-gp activities
3H-VBL
Antibodies S'Nu activity R123 accumulation accumulation
lE9 12.50 2.50a 108.50 25.00 119.50 3.50
5F/F9 (1/800) — 127.75 16.94 162.00 - 54.02
5F/F9 (1/400) 204.75 70.93 282.75 89.92
SF/F9 (1/200) 155.00 27.00 574.40 172.39k' 860.25 3251
Results are expressed as percent of control (S'Nu activity: 5.80 2.16
pmol/mg protein/mm, R123 accumulation 0.39 0.17 FAU/mg proteio,
3H-VBL accumulation 1.16 0.63 pmol/mg protein) and arc mean SEM
of 3 different experiments. Statistical analysis was performed on absolute
values.
P < 0.05 vs. control
control, NS) despite a similar 5'Nu activity in the supernatant
than in conditioned medium from MDCK-5'NU/+ (1.50 0.53
vs. 1.80 0.14 nmol/well/min, NS).
150 BA 150
100
7
50
0 25 50
0
100 0 25 50
0
1200
800
400
0
c Coichicine, ng/mI D Colchicine, ng/mI
0
C00
0
100
1200
800
400
0
0 25 50
A
Coichicine, ng/mI Colchicine, ng/mI
8
6
4
2
0
0 20
dp, iM
pm
ot
'm
g 
pr
ot
 
o
 
ro
 
a
 
a
 
0 
_
_
_
_
_
_
_
_
_
_
I-'
 
958 Ledoux et a!: Ecto-5'-Nu promotes P-gp expression
Table 4. 5'NU activity in different conditioned media
5'Nu activity nmo!/well/min
Control MDCK5'NU/-
Before incubation 0.21) 0.01 0.13 0.03 1.80 0.06a 0.00 0.00
NS
After incubation 0.16 0.17 1.62 0.40 0.00 0.00
5'NU activity was measured in usual medium (control) or in conditioned medium from MDCK-5'NU/— and MDCK-5'NU/+ cells without or with
104u aMADP, before or after 4 days of incubation with MDCK-5'NU/---. Values are means SCM of 3 experiments.
a P < 0.001 vs. control; NS, all values after incubation are not significantly different from those before incubation.
CT MDCK MDCK MDCK
-5NU/— -5NU/+ -5'NU/+
+ct3MADPMedium
Fig. 5. Effect of conditioned media on P-gp activity in MDCK-5'NU/—
cells. MDCK-5'NU/— were incubated during 96 hours with usual medium
(CT), conditioned medium from MDCK-5'NU/-- or from MDCK-
5 'NU/+,with or without io- M aJ3MADP prior to determination of R123
accumulation in the absence (E) or the presence ( of 20 jxM dp. Results
are shown as means SCM of 3 experiments (***P < 0.001 vs. MDCK-
5'NU/— medium, 5P < 0.05 vs. MDCK-5'NU/+ medium without dp).
Western blot
To acertain that the differences in MDR activity between
MDCK-5'NU/+ and MDCK-5'NU/--- cells result from different
levels of P-gp expression, we tested membrane fractions by
Western blot with the specific monoclonal anti-P-gp antibody
C219. As shown in Figure 6, P-gp could be detected in MDCK-
5'NU/— and MDCK-5'NU/+ cells with the C219 antibody, as well
as in a MDCK cell line transfected with human MDRI used as a
positive control (kind gift from Dr. M.M. Gottesman [18]). No
P-gp expression was detected in HeLa cells devoided of functional
MDR activity (as assessed by R123 and 3H-VBL accumulation,
data not shown). Expression of the protein was much more
abundant in MDCK-5'NU/+ than in MDCK-5'NU/— cells. Mem-
brane expression of P-gp in MDCK-5'NU/— cells was enhanced
by incubation with conditioned medium from MDCK-5'NU/+
cells (in the same conditions described for R123 accumulation
studies).
DISCUSSION
In the present study, we show that: (i) expression of human
5'Nu in MDCK cells induced multidrug resistance (MDR) activity
(A) (B) (C) (D) (E)
Fig. 6. Western blot of P-gp expression. Membranes of MDCK-5'NUI--
cells under control conditions i4), MDCK-5'NU/—- cells after 96 hours
incubation with conditioned medium from MDCK-5'NU/+ (B), and
MDCK-5'NU/+ cells (C) were hybridized with C219 monoclonal anti
P-gp antibody. HeLa cells (D) and a MDCK cell line transfected with
human MDR1 (F) were used as negative and positive controls, respec-
tively (representative picture of 3 experiments).
by enhancement of P-gp expression; (ii) induction of P-gp expres-
sion did not result from the enzymatic activity of 5'Nu; and (iii)
supernatant of cells that express 5'Nu confered P-gp activity to
5'Nu negative cells.
MDCK cells, a widely used model of renal epithelial cells [18,
32], were chosen for transfection of human ecto-5'Nu because
expression of the endogenous enzyme was undetectable. That
transfection conferred ecto-5'Nu activity is assessed by the fol-
lowing: (i) degradation of 5'-AMP into adcnosine occurred in the
extracellular medium; (ii) the apparent Km values are close to
those reported in glomerular cells [41]; (iii) csf3MADP, a specific
inhibitor of membrane-bound 5'Nu [7], abolished 5'Nu activity in
transfected cells, (iv) immunofluorescent studies revealed that
5'Nu was predominantly expressed in the apical membrane of
MDCK cells grown on permeable supports (not shown).
MDR activity is enhanced in 5'Nu transfected cells. (i) Both
rhodamine and vinhiastine, two dissimilar and well-documented
P-gp substrates [18, 25—28, 31, 32], were accumulated to a much
lower extent in MDCK-5'NU/+ cells than in the parental coun-
terparts. (ii) Dipyridamole, known to antagonize P-gp activity [29,
30], increased accumulation of these substrates only in MDCK-
5'NU/+ cells. (iii) Moreover, MDCK-5'NU/+ cells were more
resistant than MDCK-S'Nu/— to the cytotoxic effect of coichicine,
another P-gp substrate [2, 361. (iv) In this study, the pattern of
inhibition of R123 extrusion is consistent with previous observa-
tions [4, 42] that kidney preferentially express P-gp rather than
MDCKNU/+
MDCKNU/+
+OI3MADP
30
20
0
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MRP. R123 accumulation was increased by cyclosporine A and
verapamil, which are both inactive on MRP, but not by genistein,
a specific MRP inhibitor [351. (v) That enhancement of MDR
activity does not result from a nonspecific response to the
transfection procedure is attested by the fact that overexpression
of Na/SO4 cotransporter, another apical protein, has no effect on
R123 and 3H-VBL accumulations.
This enhancement of MDR activity in MDCK-5'NU/+ cells is
related to the induction of P-gp expression, as demonstrated by
Western blot with the anti-P-gp antibody C219. It has been
recently reported [431 that this antibody could recognize proteins
other than P-gp. However, these proteins had molecular weights
distinct from that of P-gp. The fact that the molecular weight of
the protein detected with C219 in MDCK-5'NU/+ cells was very
close to that of human P-gp expressed in a MDCK cell line
transfected with MDRI argues strongly against this hypothesis.
Even more importantly, results of Western blot analysis did
parallel those of functional studies of P-gp. The molecular weight
of P-gp in MDCK-5'NU/— cells was slightly higher than in
MDCK-5'NU/+ cells. This difference could be accounted for by
different levels of glycosylation that have been frequently de-
scribed [1, 2, 241. It is noteworthy, however, that this change in
molecular weight is not mandatory for the activity of P-gp,
inasmuch as conditioned medium from MDCK-5'NU/+ cells
enhanced P-gp activity in MDCK-5'NU/— cells without affecting
the molecular weight of the protein.
These data are in agreement with previous studies that have
suggested a link between 5'Nu and P-gp expression. Overexpres-
sion of both proteins is considered to be a serious prognostic
factor in hematologic malignancies [1, 11, 44]. In addition,
malignant cell lines selected with doxorubicin, in order to enhance
MDR expression, also overexpress ecto-5'Nu, in comparison to
parental cells [12, 13]. It was suggested that this link was sup-
ported by a metabolic interraction: 5'Nu could provide ATP
precursors to P-gp. However, the cause-effect relationship be-
tween expression of the two proteins was not clarified. Our results
show, for the first time, that 5'Nu overexpression may induce P-gp
expression.
The question then arose of the mechanism by which 5'Nu
induced P-gp expression. We first evaluated the possibility that
5'Nu enzymatic activity was instrumental in the emergence of
P-gp activity. Several lines of evidence argue against such a
mechanism. (i) Neither AMP nor adenosine, which are the
substrate and the product of this enzyme, respectively [7], affected
the activity of P-gp. (ii) Adenosine deaminase, which converts
active adenosine into inactive mosine 137], or aI3MADP, which
blocks the convcrtion of AMP into adenosine [7], did not decrease
P-gp activity. (iii) Finally, the blocking monoclonal anti-5'Nu
antibody I E9 did not affect the P-gp activity.
Our results contrast with those obtained by Ujhazy Ct al [12, 13],
who observed that n1MADP increased coichicine toxicity and
MDR activity assessed by R123 accumulation in cells overexpress-
ing 5'Nu and P-gp. The reasons for this discrepancy are not clear.
However, it is noteworthy that in these studies CsMADP by itself
affected cell viability and its inhibitory effect on 5'Nu activity was
not quantified. It may therefore be that the effect of aMADP
was independent from 5'Nu inhibition. Another possibility would
be that P-gp regulation of tumoral cells is distinct for that of
normal cells, as notably demonstrated for regulation by protein
kinases [5].
In contrast with 1E9 antibody, 5F/F9 antibody, which did not
affect the enzymatic activity of 5'Nu, inhibited P-gp activity. This
result suggests that another epitope of the enzyme is involved in
the regulation of P-gp expression. Indeed, it has been suspected
that 5'Nu plays roles independent from the conversion of AMP
into adenosine, such as tyrosine kinase activation, involvement in
lymphocyte proliferation, binding of compounds of the extracel-
lular matrix or neurite differentiation [8—10, 45—47].
The observation that conditioned medium from MDCK-
5'Nu/+ cells induced P-gp expression in MDCK-5'Nu/— suggests
that 5'Nu released in the supernatant could also enhance P-gp
expression. It is noteworthy that the presence of 5'Nu in the
supernatant of MDCK-5'NU/+ cells could be demonstrated.
Again, the enzymatic activity of 5'Nu did not play a major role in
this context since (i) aMADP did not prevent P-gp activity, and
(ii) the addition of soluble 5'Nu from snake venom, which has an
enzymatic activity close to that of the ecto-enzyme but is struc-
turaly different [8], did not elicit 5'Nu activity. Along the same
line, it has been suggested that 5'Nu, after its release from the
plasma membrane, can interact with distant sites of fixation and
induce cellular effects, such as neurite differentiation [8, 9]. From
our experiments, however, the possibility that other soluble
factors, yet to be identified, are involved in the induction of P-gp
activity cannot be definitly ruled out.
A link between 5'Nu and P-gp expression was first described in
tumoral cells [12, 13]. Our results, obtained in non-tumoral renal
epithelial cells, suggest that such a link could exist in normal cells.
Several lines of evidence argue in favor of a physiological inter-
action between the two proteins. They have a very similar tissue
distribution and, notably, both are expressed in brush border
membranes of proximal tubular cells [1, 7]. Interraction between
ecto-5'Nu and an other member of ABC transporter family, the
sulfonylurea receptor (SUR), has been reported and could be
relevant in adaptation to hypoxia [48]. Finally, it can be stressed
that both 5'Nu and P-gp are involved in nucleotide metabolism
and/or transport: 5'Nu is essential in the nucleotide salvage
pathway while P-gp was reported, at least in one study, to behave
as an ATP channel [3].
In conclusion, our results demonstrate that ecto-5'Nu overex-
pression increases membrane P-gp level and that this effect does
not results from S'Nu enzymatic activity. The physiological signif-
icance of such an interaction needs to be elucidated. Since
modulators of 5'Nu have been recently reported [23, 49—51],
these modulators might indirectly affect P-gp expression in renal
epithelial cells and, thereby, affect the capacity of these cells to
extrude endogenous or exogenous P-gp substrates.
ACKNOWLEDGMENTS
Séverinc Ledoux and Christine Leroy contributed equally to this work.
This study was supported by grants from INSERM, CNRS, Univcrsité
Paris 7, Faculté X. Bichat, Fondation pour Ia Recherchc Médicale, and
Lahoratoirc de Recherehes Physiologiqucs.
Reprint requests to Gerard Friedlander, M.D., PhD, INSERM U 426,
FacultC Xavier-Bichat, BP 416, 75870 Pari France.
APPENDIX
Abbreviations arc: P-gp, P-glycoprotcin; 5 'Nu, Ecto-5 '-nucleotidase;
R123, rhodamine 123; [3HJVBL, [3Hlvinblastine; MDCK, Madin-Darhy
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canine kidney; MDR, multidrug resistance; aI3MADP, a13-methylene-
adenosine-diphosphate; LDH, lactate dehydrogenase; EDTA, ethyl-
enediaminetetraacctic acid; PMSF, phenylmethylsulforyl fluoride.
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